It does not come as surprise, therefore, that the studies documenting roles of various miRNAs in the regulation of NADPH oxidases are, almost exclusively, conducted in models of type II diabetes or ischemic injury. This evidence concerns the gene FMO5 and type 2 diabetes mellitus.